Cabaletta Bio Q2 FY26 net loss narrows 11.69% to $51.02 million; R&D expenses rise 18.06% to $44.43 million

Reuters2026/08/13 11:33

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Cabaletta Bio posted a GAAP net loss of USD 51.02 million, improving from USD 45.13 million a year earlier.
GAAP loss per share narrowed to USD 0.34 from USD 0.73 in the prior-year quarter.
RD expenses climbed to USD 44.43 million from USD 37.64 million, while GA costs eased to USD 7.59 million from USD 8.27 million.
Cash, cash equivalents and short-term investments rose to USD 225.1 million at June 30, 2026; funding runway guided into mid-2027.
Registrational RESET-Myositis data remains slated for mid-2027, supporting a planned 2H27 BLA filing for rese-cel; RESET-SSc ILD registrational enrollment targeted for 4Q26.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cabaletta Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608130730PRIMZONEFULLFEED9809043) on August 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Cabaletta Bio Q2 FY26 net loss narrows 11.69% to $51.02 million; R&D expenses rise 18.06% to $44.43 million

You may also like

Crypto prices